Stock Screener App

Frei -

Installieren

1.04

1.96% 0.02

Tempest Therapeutics Inc (TPST)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt TPST? Forum Prognose Aktiensplit

Tempest Therapeutics Inc Aktie (TPST) Neueste Nachrichten

Tempest Therapeutics files prospectus for sale of 8.9 million shares - scanx.trade

Tempest Therapeutics (NASDAQ: TPST) lines up $50M stock facility that may heavily dilute holders - Stock Titan

Tempest partners Senlang to advance TPST-4003 in China trial - scanx.trade

Form 8K Tempest Therapeutics Inc For: 18 August By Investing.com - Investing.com South Africa

Tempest Therapeutics adjourns special meeting, sets new date for stockholder vote - Investing.com

Tempest Therapeutics Adjourns Special Stockholder Meeting Again - TipRanks

TPST Q1 2026 Earnings: Wider-Than-Expected Losses as Shares Gain 11.33%Balance Sheet Strength - vinanet.vn

Tempest Therapeutics (TPST) Stock Forum and Discussion - Moomoo

TPST Q1 2026 Earnings: EPS Deeply Misses Estimates as No Revenue ReportedPositive Surprise Momentum - Vinanet

TPST Q1 2026 Earnings: Clinical-Stage Biotech Reports Deep EPS Miss as Shares Slide 13.25%EPS Surprise History - vinanet.vn

Tempest Therapeutics Cash Drops to $0.8M Amid Recent Asset Acquisition - Minichart

Tempest Therapeutics Secures Up to $50 Million Equity Facility From Lincoln Park - Minichart

Tempest Therapeutics Cash Drops to $0.8 Million, Raising Going-Concern Risk - Minichart

Form 8K Tempest Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Tempest Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Tempest Therapeutics Secures Flexible $50 Million Equity Facility - TipRanks

Tempest Therapeutics Q2 loss narrows to $5.2m; advances CAR-T pipeline - scanx.trade

Tempest TherapeuticsEnters $50 Million Common Stock Purchase Agreement With Lincoln Park - TradingView

Tempest Therapeutics (TPST) expands CAR-T pipeline amid $32.9M loss and cash strain - Stock Titan

Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors - Quiver Quantitative

Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance

Tempest Therapeutics (TPST) Surges 13% as Biotech Momentum Builds Above Key SupportAnalyst Downgrade Signals - vinanet.vn

Tempest Therapeutics Inc expected to post a loss of 30 cents a shareEarnings Preview - TradingView

Tempest Therapeutics (TPST) Gains 3% as Biotech Stock Holds Ground Above $0.86 SupportFactor Momentum - vinanet.vn

Tempest Therapeutics (TPST) Slides to $0.86, Testing Support Near $0.82Positive Gamma - dars.gov.et

Tempest Therapeutics (TPST) Shows Modest Uptick, Holding Above Key SupportPrice Target - vinanet.vn

Tempest Therapeutics Inc (TPST) Institutional Confidence - TradingKey

Tempest Therapeutics Adjourns Vote on Governance Changes - TipRanks

Tempest Therapeutics Inc (TPST) Cash Flow - TradingKey

TPST|Tempest Therapeutics Inc|Price:0.942|Chg%:+0.016 - TradingKey

Tempest Therapeutics Inc (TPST) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

TradingKey - TradingKey

Tempest Therapeutics Inc (TPST) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Tempest Therapeutics, Inc. Revenue Breakdown – NASDAQ:TPST - TradingView

Tempest Therapeutics Inc (TPST) Valuation: PE, PB & Fair Value Analysis - TradingKey

TPST Q1 2026 Earnings: Wide EPS Miss Highlights Cash Burn ChallengesEarnings Growth Forecast - vinanet.vn

Tempest Therapeutics inks China in vivo CAR-T deal - TipRanks

Tempest Therapeutics, Inc. and Heibei Senlang Biotechnology Co., Ltd. Enter into Product Development and Investigator-Initiated Trial Collaboration Agreement - marketscreener.com

Tempest Therapeutics (TPST) Pulls Back to $0.97, Testing Key SupportSign of Weakness - dars.gov.et

Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases - Quiver Quantitative

Tempest Announces Development Collaboration with Senlang - GlobeNewswire

TPST Q1 2026 Earnings: Wide EPS Miss Highlights Ongoing Clinical-Stage LossesRevenue Per Share - vinanet.vn

Tempest Therapeutics (TPST) Inches Higher Near Resistance as Trading Remains SubduedDeath Cross - vinanet.vn

Tempest Therapeutics (TPST) plans vote on supermajority and written-consent changes - Stock Titan

William Drake Richey Net Worth (2026) - GuruFocus

Tempest advances next-generation in vivo CAR T pipeline - BioWorld News

Tempest Therapeutics (TPST) Slips 3.74% as Stock Tests Key Support ZonePut Call Ratio - vinanet.vn

Tempest plans trial of in vivo CAR-T candidate for autoimmune diseases By Investing.com - Investing.com South Africa

Tempest Therapeutics Announces Advancement of Lead In Vivo CAR-T Candidate TPST-4003 into Planned Autoimmune Disease Trial - Quiver Quantitative

Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, - GlobeNewswire

Tempest's planned CAR-T study targets myasthenia gravis and MS - Stock Titan

Tempest Therapeutics (TPST) Stabilizes at $1.0 Support Level After Modest UptickHead and Shoulders - vinanet.vn

Tempest Therapeutics (NASDAQ: TPST) registers 2.43M shares for resale tied to warrants - Stock Titan

[EFFECT] Tempest Therapeutics, Inc. SEC Filing - Stock Titan

Tempest Therapeutics (NASDAQ: TPST) seeks shareholder vote to amend charter - Stock Titan

Tempest Therapeutics (TPST) Edges Lower as Stock Hovers Near Key Support LevelWyckoff Accumulation - po-news-eg.net

Enterprise value to revenue forward of Tempest Therapeutics, Inc. – NASDAQ:TPST - TradingView

TPST Q1 2026 Earnings: Deep EPS Miss as Clinical-Stage Biotech Reports $2.53 Loss Per ShareEarnings Growth Analysis - DonanımHaber

Tempest Therapeutics (TPST) Rallies Modestly as Stock Holds Above Key SupportMomentum ETF - dars.gov.et

Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer - GlobeNewswire

Tempest Therapeutics Registers 2.43 Million Shares for Resale - Moomoo

Form S-3 Tempest Therapeutics Inc For: 26 June By Investing.com - Investing.com Nigeria

RPRX

$61.31

1.21%

INSM

$125.77

0.55%

BNTX

$116.57

5.12%

ALNY

$236.22

3.02%

ONC

$374.47

1.44%

RVMD

$209.46

1.07%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters